Logo image
Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization
Journal article   Peer reviewed

Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization

Caitlin D Lemke-Miltner, Sue E Blackwell, Chaobo Yin, Anna E Krug, Aaron J Morris, Arthur M Krieg and George J Weiner
The Journal of immunology (1950), Vol.204(5), pp.1386-1394
03/01/2020
DOI: 10.4049/jimmunol.1900742
PMCID: PMC7033003
PMID: 31953355

View Online

Abstract

The immunologic and therapeutic effects of intratumoral (IT) delivery of a novel virus-like particle as a lymphoma immunotherapy were evaluated in preclinical studies with human cells and a murine model. CMP-001 is a virus-like particle composed of the Qβ bacteriophage capsid protein encapsulating an immunostimulatory CpG-A oligodeoxynucleotide TLR9 agonist. In vitro, CMP-001 induced cytokine production, including IFN-α from plasmacytoid dendritic cells, but only in the presence of anti-Qβ Ab. In vivo, IT CMP-001 treatment of murine A20 lymphoma enhanced survival and reduced growth of both injected and contralateral noninjected tumors in a manner dependent on both the ability of mice to generate anti-Qβ Ab and the presence of T cells. The combination of IT CMP-001 with systemic anti-PD-1 enhanced antitumor responses in both injected and noninjected tumors. IT CMP-001 alone or combined with anti-PD-1 augmented T cell infiltration in tumor-draining lymph nodes. We conclude IT CMP-001 induces a robust antitumor T cell response in an anti-Qβ Ab-dependent manner and results in systemic antitumor T cell effects that are enhanced by anti-PD-1 in a mouse model of B cell lymphoma. Early-phase clinical evaluation of CMP-001 and anti-PD-1 combination therapy in lymphoma will begin shortly, based in part on these results.
Animals Antibodies, Neoplasm - immunology Cell Line, Tumor Female Humans Immunity, Cellular - drug effects Immunization Lymphoma - immunology Lymphoma - pathology Lymphoma - therapy Mice Mice, Knockout Oligodeoxyribonucleotides - pharmacology Toll-Like Receptor 9 - agonists Toll-Like Receptor 9 - immunology Vaccines, Virus-Like Particle - pharmacology

Details

Logo image